NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD
22.7
-7.93 (-25.89%)
The current stock price of VERA is 22.7 USD. In the past month the price increased by 3.04%. In the past year, price decreased by -41.04%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.48 | 335.32B | ||
AMGN | AMGEN INC | 13.99 | 156.11B | ||
GILD | GILEAD SCIENCES INC | 14.53 | 139.89B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 115.69B | ||
REGN | REGENERON PHARMACEUTICALS | 11.13 | 53.25B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 39.23B | ||
ARGX | ARGENX SE - ADR | 101.9 | 35.78B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.54 | 27.66B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
NTRA | NATERA INC | N/A | 22.36B | ||
BIIB | BIOGEN INC | 8.42 | 19.51B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.29B |
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company is headquartered in Brisbane California, California and currently employs 112 full-time employees. The company went IPO on 2021-05-14. The firm is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, it is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. The company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. The company retains all global developmental and commercial rights to atacicept and MAU868.
VERA THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 1200
Brisbane California CALIFORNIA 14623 US
CEO: Marshall Fordyce
Employees: 72
Phone: 16507700077
The current stock price of VERA is 22.7 USD. The price decreased by -25.89% in the last trading session.
The exchange symbol of VERA THERAPEUTICS INC is VERA and it is listed on the Nasdaq exchange.
VERA stock is listed on the Nasdaq exchange.
19 analysts have analysed VERA and the average price target is 67.25 USD. This implies a price increase of 196.24% is expected in the next year compared to the current price of 22.7. Check the VERA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VERA THERAPEUTICS INC (VERA) has a market capitalization of 1.45B USD. This makes VERA a Small Cap stock.
VERA THERAPEUTICS INC (VERA) currently has 72 employees.
VERA THERAPEUTICS INC (VERA) has a support level at 18.86 and a resistance level at 22.71. Check the full technical report for a detailed analysis of VERA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
VERA does not pay a dividend.
VERA THERAPEUTICS INC (VERA) will report earnings on 2025-08-06, before the market open.
VERA THERAPEUTICS INC (VERA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3).
The outstanding short interest for VERA THERAPEUTICS INC (VERA) is 11.8% of its float. Check the ownership tab for more information on the VERA short interest.
ChartMill assigns a technical rating of 3 / 10 to VERA. When comparing the yearly performance of all stocks, VERA is a bad performer in the overall market: 90.5% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to VERA. While VERA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months VERA reported a non-GAAP Earnings per Share(EPS) of -3. The EPS decreased by -44.93% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -28.76% | ||
ROE | -32.8% | ||
Debt/Equity | 0.1 |
ChartMill assigns a Buy % Consensus number of 84% to VERA. The Buy consensus is the average rating of analysts ratings from 19 analysts.